OTCPK:DTHR

Stock Analysis Report

Executive Summary

Dthera Sciences engages in developing a digital therapeutic technology to deliver reminiscence therapy to patients suffering from Alzheimer’s disease and dementia.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Dthera Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.02%

DTHR

1.8%

US Healthcare Services

2.3%

US Market


1 Year Return

-91.7%

DTHR

13.0%

US Healthcare Services

5.6%

US Market

Return vs Industry: DTHR underperformed the US Healthcare Services industry which returned 13% over the past year.

Return vs Market: DTHR underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

DTHRIndustryMarket
7 Day-0.02%1.8%2.3%
30 Day-16.7%-1.5%-1.0%
90 Day-33.3%-6.2%-0.7%
1 Year-91.7%-91.7%13.2%13.0%7.9%5.6%
3 Yearn/a56.8%56.2%45.6%36.3%
5 Yearn/a52.1%51.0%65.8%47.6%

Price Volatility Vs. Market

How volatile is Dthera Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dthera Sciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Dthera Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Dthera Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of DTHR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Dthera Sciences regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Dthera Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dthera Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of DTHR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Dthera Sciences's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Dthera Sciences performed over the past 5 years?

-37.7%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DTHR is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare DTHR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DTHR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: DTHR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: DTHR is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DTHR is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Dthera Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: DTHR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: DTHR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: DTHR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: DTHR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: DTHR has a low level of unsold assets or inventory.

Debt Coverage by Assets: DTHR has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if DTHR has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DTHR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Dthera Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DTHR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DTHR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DTHR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DTHR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DTHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Dthera Sciences's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average board tenure


CEO

Ed Cox (38yo)

3.1yrs

Tenure

US$116,395

Compensation

Mr. Edward M. Cox, also known as Ed, CLP, has been Chairman, Chief Executive Officer and President at Dthera Sciences since September 21, 2016 and serves as its Chief Financial Officer. Mr. Cox has been th ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Ed's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Ed's compensation with company performance.


Board Age and Tenure

3.1yrs

Average Tenure

54yo

Average Age

Experienced Board: DTHR's board of directors are considered experienced (3.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Ed Cox (38yo)

    Chairman

    • Tenure: 3.1yrs
    • Compensation: US$116.40k
  • Dave Keene (42yo)

    Founder

    • Tenure: 3.1yrs
    • Compensation: US$121.54k

Board Members

  • Steve Martin (58yo)

    Director

    • Tenure: 1.5yrs
  • Amir Kalali (54yo)

    Chairman of Scientific Advisory Board & Director

    • Tenure: 1yrs
  • Ed Cox (38yo)

    Chairman

    • Tenure: 3.1yrs
    • Compensation: US$116.40k
  • Dave Keene (42yo)

    Founder

    • Tenure: 3.1yrs
    • Compensation: US$121.54k
  • Larry Morgan (68yo)

    Director

    • Tenure: 3.1yrs

Company Information

Dthera Sciences's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dthera Sciences
  • Ticker: DTHR
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$1.355m
  • Shares outstanding: 2.71m
  • Website: https://www.dthera.com

Number of Employees


Location

  • Dthera Sciences
  • 7310 Miramar Road
  • Suite 350
  • San Diego
  • California
  • 92126
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DTHROTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2016

Biography

Dthera Sciences engages in developing a digital therapeutic technology to deliver reminiscence therapy to patients suffering from Alzheimer’s disease and dementia. Its lead product is ReminX, an artificial ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:41
End of Day Share Price2019/10/15 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.